Abbott revenue misses as heart devices eclipse diabetes gains

Abbott Laboratories fell just short of Wall Street estimates for quarterly revenue on Wednesday, as weakness in the medical device maker's cardiovascular business overshadowed strong performance in its fast-growing diabetes care unit.